Therefore, a “dual-biomarker system” including the expression of MXRA8 and the deficiency of ZAP is developed here, which can superiorly correlate with the efficacy of OVM in breast, liver, cervix and colon tumor cells as well as liver and kidney surgical cancer explants. This evidence concerns the gene ZC3HAV1 and cancer.